How We Evaluate Off-Label Opportunities
Plausibility is not evidence. The IYGAS framework for deciding whether a molecular finding justifies an off-label treatment, and when it does not.
Plausibility is not evidence. Precision oncology frequently encounters situations where a molecular alteration appears to match a treatment not approved for that specific tumor type, the so-called off-label opportunity.
The difficulty is that generating off-label plausibilities is easy; determining whether they are clinically meaningful is the hard part. “Is there a drug for this gene?” is not the question we ask. “Is there enough evidence to justify considering this drug for this patient?” is. This distinction is critical.
“Is there a drug for this gene?” is not the question we ask. “Is there enough evidence to justify considering this drug for this patient?” is.
Why off-label opportunities exist
Off-label situations arise for several reasons: a rare molecular alteration occurs in an uncommon tumor; a targeted therapy is approved in one cancer but not another; a molecular mechanism appears biologically relevant but lacks regulatory approval; or the patient has exhausted standard treatment options.
These situations are common in advanced cancer care. But rarity does not reduce the need for evidence, it increases it.
The IYGAS off-label evaluation framework
Before an off-label opportunity is included in a report, it must pass through several layers of review: six questions, asked in order.
1Is the alteration real?
Before discussing treatment, we verify technical quality, variant allele frequency, tumor purity, possible artifacts, and, where relevant, clonal hematopoiesis (CHIP). An off-label recommendation built on an uncertain finding is unreliable from the ground up.
2Is the alteration driving the tumor?
Not every mutation deserves to be targeted. We assess driver versus passenger status, clonality, resistance biology, and co-occurring alterations. Targeting a passenger alteration is unlikely to produce meaningful benefit no matter how attractive the drug appears.
3Is the biology convincing?
A biologically plausible mechanism is necessary but not sufficient; many treatments that look promising in laboratory models ultimately fail in clinical trials. For this reason, we clearly separate two concepts that must never be conflated:
- Clinical evidence, evidence that a treatment benefits patients.
- Biological plausibility, evidence that a treatment might benefit patients.
4What is the actual level of evidence?
Every off-label opportunity is categorized by the strength of the evidence supporting it. The tier is always stated explicitly.
Strong clinical evidence Tier 1
Prospective trials, consistent clinical outcomes, and guideline recognition.
Emerging clinical evidence Tier 2
Early-phase trials, small cohorts, and retrospective analyses.
Biological hypothesis Tier 3
Preclinical data, mechanistic rationale, and laboratory evidence.
5Is there a better-supported alternative?
An off-label option should never replace a stronger, evidence-based strategy. We always evaluate standard-of-care treatments, guideline-supported options, and clinical trial opportunities before considering weaker alternatives.
An off-label option should expand the options, not replace the stronger ones.
6Is it realistically accessible?
An elegant molecular hypothesis has little value if it cannot be implemented. Practical considerations include drug availability, regulatory status, reimbursement, geographic access, and clinical trial eligibility. A recommendation must be realistic, not just theoretical.
What we don't do
The discipline of off-label assessment is defined as much by what we refuse to do as by what we recommend. We do not:
- Present an off-label treatment as standard of care
- Overstate weak evidence
- Conceal uncertainty
- Disregard stronger alternatives
- Treat biological rationale as equivalent to clinical benefit
Where uncertainty exists, it is stated explicitly.
The role of clinical trials
Many of today's standard treatments were once considered experimental. For this reason, clinical trials often represent the most appropriate setting for strategies that are biologically compelling but not yet proven.
Wherever possible, trial enrollment is considered before unsupported off-label use.
Honest output
When an off-label opportunity appears in an IYGAS report, it is presented transparently. The report states:
- The biological rationale
- The level of evidence
- The expected uncertainty
- Access considerations
- Where the option sits within the treatment sequence
The goal is not to recommend a treatment, it is to provide a framework for informed clinical decision-making.
The point
Off-label assessment is where precision oncology is most vulnerable to optimism. It is also where disciplined reasoning matters most. Finding a gene-drug match is easy; determining whether that match is meaningful, evidence-based, and appropriate for a specific patient is the real challenge.
The goal is not to generate possibilities, but to determine which possibilities deserve serious consideration, and why.
This content is for educational purposes only. It does not constitute individual medical advice and does not replace the judgment of the treating physician.
Submit a case for expert molecular review
NGS Advisory reviews your existing NGS report against current guidelines, clarifies the exact variant and its actionability for your tumor type, and delivers a structured, calibrated second opinion.